ImmuPharma (LON:IMM) Shares Up 25.3% - What's Next?

Key Points

• ImmuPharma plc stock price surged by 25.3% on a recent trading day, reaching a high of GBX 19.35 ($0.26) after closing at GBX 13.98 ($0.19).
• Approximately 65 million shares were traded during the day, marking an increase of 677% compared to the average daily volume.
• The company's negative PE ratio stands at -1,967.53, indicating financial challenges as it anticipates posting significant losses for the current year.

ImmuPharma plc (LON:IMM - Get Free Report)'s stock price rose 25.3% during mid-day trading on Monday . The company traded as high as GBX 19.35 ($0.26) and last traded at GBX 17.51 ($0.24). Approximately 65,638,188 shares traded hands during mid-day trading, an increase of 677% from the average daily volume of 8,446,959 shares. The stock had previously closed at GBX 13.98 ($0.19).

ImmuPharma Stock Up 2.9%

The stock has a market capitalization of £62.47 million, a PE ratio of -1,404.49 and a beta of 1.53. The stock has a fifty day moving average of GBX 4.07 and a 200-day moving average of GBX 3.21.

ImmuPharma (LON:IMM - Get Free Report) last released its earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share (EPS) for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. Equities research analysts expect that ImmuPharma plc will post -339.0000022 EPS for the current year.

About ImmuPharma

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.